All In Biotech

Drug Trial Radar · NCT05375903

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UGN-301 (Zalifrelimab) Administered Intravesically as Monotherapy and in Combination With Other Agents in Patients With Recurrent NMIBC

Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Jun 1, 2022

Primary completion

Jan 9, 2026

Study completion Jan 9, 2026

Sponsor

Lead sponsor
UroGen Pharma Ltd.Industry
Sponsor type
Industry
First posted
May 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the safety and determine the recommended Phase 2 dose (RP2D) of UGN-301 (zalifrelimab) administered intravesically as monotherapy and in combination with other agents in patients with recurrent NMIBC.

Conditions

  • Non-muscle Invasive Bladder Cancer
  • NMIBC
  • Carcinoma in Situ of Bladder
  • Bladder Cancer
  • Urothelial Carcinoma Bladder
  • Urothelial Carcinoma Recurrent

Interventions

  • UGN-301Drug

    Induction Period: Intravesical administration once weekly for 6 weeks. Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).

  • UGN-201Drug

    Induction Period: Intravesical administration once weekly for 6 weeks. Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).

  • GemcitabineDrug

    Induction Period: Intravesical administration once weekly for 6 weeks. Optional Maintenance Period: Intravesical administration once every 3 months (at 6, 9, and 12 months after the start of treatment).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs)Time frame: Up to 15 months
  2. Concentration of UGN-301 in blood and urineTime frame: 6 weeks
  3. Complete response rate (CRR)Time frame: 3 months
  4. Recurrence-free survival (RFS) rateTime frame: 3 months

Locations

13 sites in 3 countries. Site status is shown where the registry gives one.

  • Arkansas Urology

    Little Rock, Arkansas

  • UCLA - University of California

    Los Angeles, California

  • Florida Urology Partners, LLC

    Tampa, Florida

  • Johns Hopkins University

    Baltimore, Maryland

  • Manhattan Medical Research

    New York, New York

  • Clinical Research Solutions

    Middleburg Heights, Ohio

  • Penn State Milton S Hershey Medical Center

    Hershey, Pennsylvania

  • I.R.C.C.S. Ospedale San Raffaele

    Milan, Italy

  • National Tumor Institute Fondazione G. Pascale

    Naples, Italy

  • Istituto Oncologico Veneto

    Padova, Italy

  • NEXT Oncology IOB- Hospital Quironsalud Barcelona

    Barcelona, Spain

  • Hospital Clinic de Barcelona Instituto Clinic de Nefrologia y Urologia (ICNU)

    Barcelona, Spain

  • NEXT Oncology- Hospital Quironsalud Mardrid

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.